All In Biotech

Drug Trial Radar · NCT03313778

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

161

Actual

Start

Aug 14, 2017

Primary completion

Nov 21, 2027

Study completion Nov 21, 2027

Sponsor

Lead sponsor
ModernaTX, Inc.Moderna (MRNA)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.

Conditions

  • Solid Tumors

Interventions

  • mRNA-4157Biological

    IM injection

  • PembrolizumabBiological

    Intravenous infusion

  • SoC TreatmentBiological

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse EventsTime frame: Part A and A2: Baseline through 100 days after last mRNA-4157 dose; Parts B, C, D, E1, E2, and E3: Baseline through 90 days after last pembrolizumab dose

Locations

20 sites in 4 countries. Site status is shown where the registry gives one.

  • Angeles Clinic and Research Institute

    Los Angeles, California

  • The George Washington Cancer Center

    Washington D.C., District of Columbia

  • Orlando Health Cancer Institute

    Orlando, Florida

  • Florida Cancer Specialists

    Sarasota, Florida

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • NYU Langone Medical Center

    New York, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • UT Southwest Medical Center

    Dallas, Texas

  • St Vincents Hospital Sydney

    Darlinghurst, New South Wales, Australia

  • Westmead Hospital-Cnr Hawkesbury and Darcy Road

    Westmead, New South Wales, Australia

  • One Clinical Research Perth

    Nedlands, Western Australia, Australia

  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research

    Tokyo, Japan

  • National Cancer Center East

    Kashiwa-Shi, Chiba, Japan

  • Kindai University Hospital

    Osakasayama-Shi, Ôsaka, Japan

  • National Cancer Center Hospital

    Chuo-Ku, Tokyo, Japan

  • Imperial College Healthcare NHS Trust Hammersmith Hospital

    London, United Kingdom

  • Ninewells Hospital - PPDS

    Dundee, Scotland, United Kingdom

  • Royal Mardsen Sutton

    Sutton, Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.